Durvalumab in Stage III Non-Small-Cell Lung Cancer

Matteo Santoni^{1

2}, Nicola Battelli¹, Sebastiano Buti³

Affiliations

Comment

Matteo Santoni et al. N Engl J Med. 2018.

. 2018 Mar 1;378(9):869.

doi: 10.1056/NEJMc1716426.

Matteo Santoni^{1

2}, Nicola Battelli¹, Sebastiano Buti³

No abstract available

Comment in

Durvalumab in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Özgüroğlu M. Antonia SJ, et al. N Engl J Med. 2018 Mar 1;378(9):869-870. doi: 10.1056/NEJMc1716426. N Engl J Med. 2018. PMID: 29490170 No abstract available.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators. Antonia SJ, et al. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8. N Engl J Med. 2017. PMID: 28885881 Clinical Trial.